Memorial Sloan Kettering Cancer Center
The purpose of this study is to find out whether ZEN003694 is an effective treatment for people with advanced squamous cell lung cancer with a mutation in the NSD3 gene. ZEN003694 is a type of drug called a BET inhibitor. Researchers think ZEN003694 may help here because the drug works by blocking a group of proteins called bromodomain and extra-terminal (BET) proteins, which may counteract the effect of NSD3 on tumor growth. Blocking these proteins may slow or stop the growth of the cancer.
Inclusion Criteria: * Histologically-confirmed squamous cell lung cancer * Recurrent or metastatic disease * Patients with previously treated asymptomatic brain metastases requiring no more than 10mg prednisone (or equivalent) are allowed. Patients with asymptomatic brain metastases ≤ 1cm not requiring more than 10mg prednisone (or equivalent) are allowed. * Received prior first-line therapy: platinum-based chemotherapy and immunotherapy, given either concurrently or sequentially * Eastern Cooperative Oncology Group (ECOG) PS 0-2 * Evidence of NSD3 gain or amplification by NGS, including but…
ZEN003694 60mg po qd on a 5 days on 2 days off schedule in an every 21-day cycle